X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1267) 1267
Book Review (232) 232
Publication (107) 107
Book / eBook (3) 3
Book Chapter (3) 3
Conference Proceeding (3) 3
Magazine Article (3) 3
Streaming Video (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1195) 1195
humans (769) 769
animals (619) 619
male (616) 616
benzylamines - pharmacology (426) 426
benzylamines - therapeutic use (378) 378
pharmacology & pharmacy (345) 345
rats (331) 331
benzylamines (296) 296
azetidines - therapeutic use (255) 255
anticoagulants - therapeutic use (234) 234
female (234) 234
mice (181) 181
adult (166) 166
neurosciences (158) 158
middle aged (153) 153
dose-response relationship, drug (133) 133
administration, oral (132) 132
rats, sprague-dawley (131) 131
ximelagatran (124) 124
aged (123) 123
thrombin - antagonists & inhibitors (121) 121
treatment outcome (120) 120
benzylamines - administration & dosage (119) 119
naphthalenes - therapeutic use (116) 116
analysis (107) 107
venous thromboembolism (106) 106
warfarin (106) 106
benzylamines - adverse effects (104) 104
warfarin - therapeutic use (101) 101
abridged index medicus (99) 99
disease models, animal (98) 98
sulfonamides - pharmacology (91) 91
stroke - prevention & control (88) 88
benzylamines - chemistry (86) 86
enzyme inhibitors - pharmacology (86) 86
drug therapy (84) 84
time factors (84) 84
azetidines - administration & dosage (83) 83
benzylamines - pharmacokinetics (83) 83
serotonin uptake inhibitors - therapeutic use (83) 83
double-blind (81) 81
clinical trials as topic (79) 79
rats, wistar (79) 79
anticoagulants - administration & dosage (78) 78
double-blind method (78) 78
anticoagulants (77) 77
amidines - pharmacology (76) 76
hematology (76) 76
melagatran (76) 76
anticoagulants - adverse effects (75) 75
clinical neurology (75) 75
thromboembolism - prevention & control (75) 75
glycine - analogs & derivatives (74) 74
peripheral vascular disease (73) 73
biochemistry & molecular biology (70) 70
randomized controlled trials as topic (70) 70
atrial fibrillation - drug therapy (69) 69
nitric oxide (69) 69
medicine, general & internal (67) 67
pharmacokinetics (66) 66
premature ejaculation (66) 66
prevention (66) 66
research (66) 66
venous thrombosis - prevention & control (66) 66
atrial fibrillation - complications (65) 65
azetidines - adverse effects (65) 65
direct thrombin inhibitor (65) 65
azetidines - pharmacology (63) 63
benzylamines - metabolism (63) 63
rat (63) 63
article (61) 61
expression (60) 60
care and treatment (59) 59
mice, inbred c57bl (59) 59
atrial fibrillation (58) 58
cardiac & cardiovascular systems (58) 58
brain (57) 57
deep-vein thrombosis (57) 57
stroke (57) 57
anticoagulants - pharmacology (56) 56
in vitro techniques (56) 56
physiological aspects (56) 56
risk factors (56) 56
dapoxetine (55) 55
medicine & public health (55) 55
inflammation (54) 54
kinetics (54) 54
psychiatry (54) 54
stroke prevention (54) 54
alanine - analogs & derivatives (53) 53
ejaculation - drug effects (53) 53
norepinephrine - metabolism (53) 53
azetidines - pharmacokinetics (52) 52
prodrugs - therapeutic use (52) 52
cells, cultured (51) 51
drugs (51) 51
pharmacology/toxicology (51) 51
serotonin (51) 51
chemistry, medicinal (50) 50
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1190) 1190
German (23) 23
French (17) 17
Chinese (11) 11
Italian (10) 10
Spanish (9) 9
Japanese (4) 4
Turkish (4) 4
Hungarian (2) 2
Polish (2) 2
Portuguese (2) 2
Russian (2) 2
Dutch (1) 1
Finnish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JAMA - Journal of the American Medical Association, ISSN 0098-7484, 01/2018, Volume 319, Issue 2, pp. 130 - 142
IMPORTANCE New therapeutic approaches for Alzheimer disease (AD) are needed. OBJECTIVE To assess whether idalopirdine, a selective 5-hydroxytryptamine-6... 
DONEPEZIL | 5-HT6 RECEPTOR ANTAGONIST | MODERATE | MEDICINE, GENERAL & INTERNAL | DOUBLE-BLIND | SEROTONIN | SB-742457 | RATING-SCALE | VALIDITY | Serotonin Antagonists - administration & dosage | Benzylamines - adverse effects | Humans | Middle Aged | Male | Indans - therapeutic use | Benzylamines - administration & dosage | Indoles - administration & dosage | Dose-Response Relationship, Drug | Serotonin Antagonists - adverse effects | Treatment Failure | Aged, 80 and over | Female | Drug Therapy, Combination | Accidental Falls | Alzheimer Disease - psychology | Double-Blind Method | Alzheimer Disease - drug therapy | Serotonin Antagonists - therapeutic use | Cognition - drug effects | Indoles - adverse effects | Galantamine - therapeutic use | Piperidines - therapeutic use | Cholinesterase Inhibitors - adverse effects | Indoles - therapeutic use | Aged | Rivastigmine - therapeutic use | Cholinesterase Inhibitors - therapeutic use | Benzylamines - therapeutic use | Treatment outcome | Care and treatment | Safety and security measures | Analysis | Clinical trials | Dosage and administration | Cholinesterase inhibitors | Alzheimer's disease | Drugs | Medical research | Activities of daily living | Galantamine | Neurodegenerative diseases | Serotonin | Medical treatment | Cognitive ability | Medical services | Cognition | Patients | Cholinesterase | Randomization | Safety engineering | Donepezil | Alzheimers disease | Index Medicus | Abridged Index Medicus | Original Investigation | Research
Journal Article
Medicine (United States), ISSN 0025-7974, 10/2017, Volume 96, Issue 40, pp. e8059 - e8059
Journal Article
JAMA, ISSN 0098-7484, 02/2005, Volume 293, Issue 6, pp. 681 - 689
CONTEXT Ximelagatran, an oral direct thrombin inhibitor with a rapid onset of action and predictable antithrombotic effect, has the potential to be a simple... 
ORAL XIMELAGATRAN | ENOXAPARIN | MEDICINE, GENERAL & INTERNAL | KNEE REPLACEMENT | THERAPY | VENOUS THROMBOEMBOLISM | MELAGATRAN | INTRAVENOUS UNFRACTIONATED HEPARIN | ABSORPTION | INHIBITOR XIMELAGATRAN | SECONDARY PREVENTION | Prodrugs - administration & dosage | Recurrence | Anticoagulants - administration & dosage | Humans | Middle Aged | Male | Venous Thrombosis - complications | Heparin, Low-Molecular-Weight - therapeutic use | Warfarin - administration & dosage | Warfarin - therapeutic use | Aged, 80 and over | Adult | Female | Drug Therapy, Combination | Pulmonary Embolism - complications | Double-Blind Method | Venous Thrombosis - drug therapy | Venous Thrombosis - mortality | Anticoagulants - therapeutic use | Treatment Outcome | Azetidines - administration & dosage | Azetidines - therapeutic use | Benzylamines | Aged | Prodrugs - therapeutic use | Alanine Transaminase - metabolism | Heparin, Low-Molecular-Weight - administration & dosage | Clinical trials | Cardiac arrhythmia | Thrombolytic drugs | Medical treatment | Blood clots | Index Medicus | Abridged Index Medicus | Low-Molecular-Weight/administration & dosage/therapeutic use | Anticoagulants/administration & dosage/therapeutic use | Pulmonary Embolism/complications | Drug Therapy | MEDICIN OCH HÄLSOVETENSKAP | Alanine Transaminase/metabolism | Warfarin/administration & dosage/therapeutic use | 80 and over | Azetidines/administration & dosage/therapeutic use | Combination | Prodrugs/administration & dosage/therapeutic use | Venous Thrombosis/complications/drug therapy/mortality | Heparin | MEDICAL AND HEALTH SCIENCES
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 01/2011, Volume 57, Issue 2, pp. 173 - 180
Journal Article
Cancer Cell, ISSN 1535-6108, 2011, Volume 19, Issue 1, pp. 58 - 71
Activation of the PI3K-AKT pathway in tumors is modulated by negative feedback, including mTORC1-mediated inhibition of upstream signaling. We now show that... 
RAPAMYCIN | TARGET | FORKHEAD TRANSCRIPTION FACTOR | CELLS | INSULIN-RECEPTOR | ACTIVATION | ONCOLOGY | SIGNALING PATHWAY | PHOSPHORYLATION | UPSTREAM | HUMAN CANCER | CELL BIOLOGY | RNA, Small Interfering - genetics | Receptor, IGF Type 1 - metabolism | Protein Binding - genetics | Receptor, ErbB-3 - metabolism | Humans | Forkhead Transcription Factors - metabolism | Protein Binding - drug effects | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Receptor, ErbB-2 - antagonists & inhibitors | Phosphorylation - drug effects | Proto-Oncogene Proteins c-akt - metabolism | Quinoxalines - therapeutic use | Carcinoma, Non-Small-Cell Lung - metabolism | Receptor, ErbB-3 - genetics | Receptor Protein-Tyrosine Kinases - metabolism | Breast Neoplasms - drug therapy | Receptor, IGF Type 1 - genetics | Signal Transduction - drug effects | Mice, Nude | Models, Biological | Cell Line, Tumor | Mice | TOR Serine-Threonine Kinases | Feedback, Physiological - physiology | Quinazolines - pharmacology | Proteins - antagonists & inhibitors | Neoplasms - metabolism | Gene Expression - drug effects | Multiprotein Complexes | Receptor, ErbB-2 - metabolism | Promoter Regions, Genetic - genetics | Proto-Oncogene Proteins c-akt - genetics | Breast Neoplasms - metabolism | Mechanistic Target of Rapamycin Complex 1 | Quinoxalines - pharmacology | Receptor, Insulin - genetics | Female | Forkhead Transcription Factors - antagonists & inhibitors | Gene Expression Regulation, Neoplastic - drug effects | Drug Therapy, Combination | Gene Expression Regulation, Neoplastic - physiology | Carcinoma, Non-Small-Cell Lung - pathology | Up-Regulation - genetics | Forkhead Transcription Factors - genetics | Xenograft Model Antitumor Assays | Animals | Receptor Protein-Tyrosine Kinases - genetics | Breast Neoplasms - pathology | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Feedback, Physiological - drug effects | Receptor, Insulin - metabolism | Signal Transduction - physiology | Protein Kinase Inhibitors - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Benzylamines - pharmacology | Benzylamines - therapeutic use | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Index Medicus
Journal Article
Journal Article
Journal Article
Journal Article
American Journal of Psychiatry, ISSN 0002-953X, 05/2004, Volume 161, Issue 5, pp. 826 - 835
OBJECTIVE: Minimum therapeutic doses of paroxetine and citalopram produce 80% occupancy for the serotonin (5-HT) transporter (5-HTT). The authors used... 
H-3 PAROXETINE BINDING | ANTIDEPRESSANTS | DASB | 5-HT2 RECEPTORS | PSYCHIATRY | IN-VIVO | HIGH-AFFINITY | HUMAN-BRAIN | MAJOR DEPRESSION | UPTAKE SITES | PET | Paroxetine - pharmacokinetics | Serotonin Uptake Inhibitors - pharmacokinetics | Cyclohexanols - pharmacokinetics | Fluoxetine - pharmacokinetics | Membrane Glycoproteins - metabolism | Humans | Middle Aged | Male | Paroxetine - therapeutic use | Serotonin Plasma Membrane Transport Proteins | Carrier Proteins - drug effects | Corpus Striatum - metabolism | Dose-Response Relationship, Drug | Sertraline - pharmacokinetics | Sertraline - therapeutic use | Adult | Female | Fluoxetine - therapeutic use | Serotonin Uptake Inhibitors - therapeutic use | Nerve Tissue Proteins | Venlafaxine Hydrochloride | Carrier Proteins - metabolism | Membrane Transport Proteins | Serotonin - metabolism | Benzylamines | Corpus Striatum - drug effects | Cyclohexanols - therapeutic use | Membrane Glycoproteins - drug effects | Citalopram - pharmacokinetics | Citalopram - therapeutic use | Tomography, Emission-Computed | Corpus Striatum - diagnostic imaging | Delayed-Action Preparations | Carbon Radioisotopes | Dosage and administration | Serotonin agents | Drug therapy | Mental illness | Tomography | Mental disorders | Antidepressants | Psychiatry | Clinical outcomes | Index Medicus | Abridged Index Medicus
Journal Article
The Lancet, ISSN 0140-6736, 09/2003, Volume 362, Issue 9386, pp. 789 - 797
Despite important advances in treatment, the risk of recurrent ischaemic events is high both early and late after an acute coronary syndrome. We aimed to... 
ACTIVE FORM | MEDICINE, GENERAL & INTERNAL | DIRECT THROMBIN INHIBITOR | PHARMACOKINETICS | NO INFLUENCE | LOW-MOLECULAR-WEIGHT | HEALTHY MALE-SUBJECTS | ACUTE CORONARY SYNDROMES | UNSTABLE ANGINA | ST-SEGMENT ELEVATION | ARTERY DISEASE | Double-Blind Method | Administration, Oral | Humans | Middle Aged | Myocardial Ischemia - prevention & control | Male | Treatment Outcome | Secondary Prevention | Myocardial Infarction - drug therapy | Azetidines - therapeutic use | Benzylamines | Placebos | Female | Aged | Aspirin - therapeutic use | Myocardial Infarction - prevention & control | Prodrugs - therapeutic use | Drug Therapy, Combination | Evaluation | Care and treatment | Heart attack | Cardiovascular agents | Heart attacks | Drug therapy | Disease control | Medical treatment | Clinical outcomes | Myocardial infarction | Anticoagulants | Enzymes | Stroke | Control methods | Mortality | Prophylaxis | Thrombin | Acetylsalicylic acid | Patients | Investigations | Bleeding | Elevation | Randomization | Motivation | Acids | Ischemia | Infarction | Acute coronary syndromes | Health risk assessment | Drug dosages | Index Medicus | Abridged Index Medicus | Comparative Study | Recurrence/prevention & control | Aspirin/therapeutic use | Administration; Oral | Myocardial Ischemia/prevention & control | Drug Therapy; Combination | Research Support; Non-U.S. Gov't | Azetidines/therapeutic use | Myocardial Infarction/drug therapy/prevention & control | Prodrugs/therapeutic use
Journal Article